$SGHT

Rodberg James sold $37K of SGHT

Rodberg James (Chief Financial Officer) sold 6,902 shares of Sight Sciences, Inc. (SGHT) at $5.36 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodberg James
Published Jul 6, 2026, 11:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SGHT
Neutral
medium confidence
Mentioned
$SGHT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGHTNeutralLow
01

Why it matters

Because the sale is explicitly under a pre-arranged 10b5-1 plan and is relatively small in dollar terms, it is more likely to be informational for monitoring than a catalyst.

02

Market read

Traders may log the sale for insider-flow tracking, but it does not provide new operational or financial guidance.

03

What to watch

The disclosure doesn’t indicate whether other insiders sold/bought around the same time, nor does it quantify total insider activity beyond this single transaction.

Relevance 2/10Novelty 3/10Timing: Filed after-hours on 2026-07-06; relevant for next-session sentiment/flow checks.

Background

The article is a primary-source SEC Form 4 insider transaction for Sight Sciences, Inc., reported by the CFO.

Company-level read

Ticker impact

$SGHTNeutralMedium confidence
Context

Sight Sciences CFO Rodberg James sold 6,902 shares for about $37.0K under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a small dollar value relative to typical market moves and explicitly states a pre-arranged 10b5-1 plan.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially in thinly traded names.

Key entities

  • Sight Sciences, Inc.

    Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.

  • Rodberg James

    Chief Financial Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SGHTHighAI 8/10

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

$SGHTMedAI 8/10

Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

$SGHTHighAI 8/10

TearCare is the first and only treatment indicated to improve gland function in dry-eye patients

Sight Sciences (SGHT) announced that the FDA expanded the TearCare System's indication to include improving meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first and only treatment with this indication, effective August 18, 2026. The update also incorporates optional debridement into the system's treatment approach.

$SGHTMedAI 8/10

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA expanded approval for its TearCare System, now the only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). The update includes optional debridement, enhancing its comprehensive approach to treating MGD. According to the company, this milestone reflects its commitment to advancing dry eye disease treatment.

$SGHTMedAI 8/10

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.